Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):328-333.
doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

M Benthe Muntinghe-Wagenaar  1 , T Jeroen N Hiltermann  1
Affiliations
Editorial

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

M Benthe Muntinghe-Wagenaar et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Immune checkpoint inhibition; biomarker; non-small cell lung cancer (NSCLC); programmed death-ligand 1 (PD-L1).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-966/coif). M.B.M.W. reports travel grants from AACR-BMS and NRS. T.J.N.H. reports research funds from Roche, BMS, and AZD. The authors have no other conflicts of interest to declare.

Comment on

  • Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.

References

    1. Zhang B, Liu Y, Zhou S, et al. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Int Immunopharmacol 2020;80:106214. 10.1016/j.intimp.2020.106214 - DOI - PubMed
    1. van de Haar J, Mankor JM, Hummelink K, et al. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer. Clin Cancer Res 2024;30:1307-18. 10.1158/1078-0432.CCR-23-4027 - DOI - PMC - PubMed
    1. Besse B, Pons-Tostivint E, Park K, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med 2024;30:716-29. 10.1038/s41591-024-02808-y - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed

LinkOut - more resources